Raed Alroughani Selected Research

Fingolimod Hydrochloride (FTY720)

4/2022	Multiple Sclerosis Relapses Following Cessation of Fingolimod.
1/2022	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
12/2021	Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19.
11/2021	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
8/2021	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
6/2021	Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19.
4/2021	Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
4/2021	Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
6/2019	An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion.
1/2019	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raed Alroughani Research Topics

Disease

47	Multiple Sclerosis 04/2022 - 01/2012
17	Relapsing-Remitting Multiple Sclerosis 01/2022 - 09/2014
7	COVID-19 05/2022 - 06/2021
5	Migraine Disorders (Migraine) 04/2022 - 01/2015
5	Disease Progression 09/2021 - 01/2015
5	Headache (Headaches) 08/2021 - 12/2013
3	Ganglion Cysts (Ganglion) 07/2019 - 01/2017
2	Infections 12/2021 - 06/2021
2	Neuromyelitis Optica (Devic's Disease) 02/2020 - 02/2020
2	Spontaneous Abortion (Miscarriage) 02/2019 - 01/2016
2	Atrophy 04/2018 - 01/2017
1	Tension-Type Headache (Tension Headache) 08/2021
1	Neoplasms (Cancer) 01/2021
1	Food Hypersensitivity (Food Allergy) 09/2020
1	Premature Birth (Birth, Premature) 02/2019
1	Inflammation (Inflammations) 01/2019
1	Chronic Progressive Multiple Sclerosis 01/2019
1	Primary Headache Disorders 12/2018
1	Headache Disorders (Headache Syndromes) 12/2018
1	Demyelinating Diseases (Demyelinating Disease) 04/2018
1	Rare Diseases (Rare Disease) 01/2018
1	Lymphopenia (Lymphocytopenia) 01/2018
1	Bradycardia 08/2017
1	Sclerosis 08/2017
1	Vitamin D Deficiency 01/2016
1	Epstein-Barr Virus Infections 08/2015

Drug/Important Bio-Agent (IBA)

19	Fingolimod Hydrochloride (FTY720)FDA Link 04/2022 - 04/2014
13	Natalizumab (Tysabri)FDA Link 01/2022 - 04/2014
9	Dimethyl FumarateIBA 01/2022 - 12/2017
8	InterferonsIBA 01/2022 - 01/2013
8	Alemtuzumab (Campath)FDA Link 12/2021 - 01/2017
6	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 03/2015
5	teriflunomideIBA 01/2022 - 01/2019
5	Cladribine FDA LinkGeneric 01/2022 - 06/2019
5	Retinaldehyde (Retinal)IBA 07/2019 - 12/2015
4	TabletsIBA 01/2022 - 06/2019
3	ocrelizumabIBA 01/2022 - 06/2019
3	Pharmaceutical PreparationsIBA 01/2022 - 04/2015
3	Interferon beta-1a FDA Link 12/2021 - 01/2013
2	Rituximab (Mabthera)FDA Link 05/2022 - 11/2021
2	Analgesics (Analgesic Drugs)IBA 08/2021 - 12/2018
2	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2020 - 01/2016
2	Interferon-betaIBA 01/2017 - 04/2015
2	Antigen-Antibody Complex (Immune Complex)IBA 01/2017 - 02/2015
2	GadoliniumIBA 01/2017 - 01/2015
1	HomocysteineIBA 04/2022
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 04/2022
1	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 02/2022
1	Synthetic Vaccines (Recombinant Vaccines)IBA 02/2022
1	siponimodIBA 11/2021
1	VaccinesIBA 11/2021
1	Tobacco Smoke Pollution (Passive Smoking)IBA 09/2020
1	anti-aquaporin 4 autoantibodyIBA 02/2020
1	Immunoglobulin G (IgG)IBA 02/2020
1	Type A Botulinum Toxins (Botox)FDA Link 01/2020
1	preemptIBA 01/2020
1	LeptinIBA 11/2019
1	Angiopoietin-like ProteinsIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	Cytidine Diphosphate (CDP)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Genetic Markers (Genetic Marker)IBA 10/2016
1	HLA-DRB1 Chains (HLA DRB1)IBA 08/2015
1	AntigensIBA 08/2015
1	methyl 4-azidophenylacetimidate (APAI)IBA 01/2015
1	Methylprednisolone FDA LinkGeneric 01/2015
1	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2015

Therapy/Procedure

30	Therapeutics 05/2022 - 01/2012
3	Immunotherapy 01/2021 - 01/2017
3	Injections 10/2016 - 03/2015
2	Immunomodulation 03/2017 - 04/2016
1	Precision Medicine 09/2021
1	Induced Abortion (Induced Abortions) 02/2019
1	Traditional Medicine (Folk Remedies) 12/2018